Keros Therapeutics (KROS) Stock Forecast & Price Target

→ Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad)

$44.65

+0.07 (+0.16%)

(As of 06/18/2024 ET)

Keros Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 7 Analyst Ratings

Consensus Price Target

$86.00
92.61% Upside

High Forecast	$105.00
Average Forecast	$86.00
Low Forecast	$60.00

Type	Current Forecast 6/20/23 to 6/19/24	1 Month Ago 5/21/23 to 5/20/24	3 Months Ago 3/22/23 to 3/21/24	1 Year Ago 6/20/22 to 6/20/23
Consensus Rating	Buy	Buy	Buy	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$86.00	$86.00	$86.83	$103.75
Forecasted Upside	92.61% Upside	53.30% Upside	57.71% Upside	106.73% Upside

Get Keros Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter.

Ad InvestorPlace

Must-See: Elon’s New Invention is Absolutely Insane

Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.

Click here for the full story…

KROS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

KROS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Keros Therapeutics Stock vs. The Competition

Type	Keros Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.70	2.50
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	92.61% Upside	985.06% Upside	11.30% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
6/18/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00	+122.22%
6/18/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00	+124.32%
3/27/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$105.00	+59.60%
2/29/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$86.00	+25.51%
2/21/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Phipps Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
12/8/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$60.00	+68.97%
7/26/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$65.00	+51.27%
2/14/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
2/14/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
12/13/2022	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$95.00 ➝ $105.00	+121.89%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:08 AM ET.

KROS Forecast - Frequently Asked Questions

What is Keros Therapeutics's stock forecast and purchase recommendation?: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Keros Therapeutics is $86.00, with a high forecast of $105.00 and a low forecast of $60.00. The consensus rating for Keros Therapeutics stock is Buy based on the current 7 buy ratings for KROS. Learn more on KROS's analyst rating history.
Do Wall Street analysts like Keros Therapeutics more than its competitors?: Analysts like Keros Therapeutics more than other "medical" companies. The consensus rating for Keros Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how KROS compares to other companies.
Does Keros Therapeutics's stock price have much upside?: According to analysts, Keros Therapeutics's stock has a predicted upside of 70.65% based on their 12-month stock forecasts.

What analysts cover Keros Therapeutics?: Keros Therapeutics has been rated by research analysts at HC Wainwright, Piper Sandler, and Truist Financial in the past 90 days.